Immune responses of infants to infection with respiratory viruses and live attenuated respiratory virus candidate vaccines
Identifieur interne : 001769 ( Istex/Curation ); précédent : 001768; suivant : 001770Immune responses of infants to infection with respiratory viruses and live attenuated respiratory virus candidate vaccines
Auteurs : James E. Crowe Jr. [États-Unis]Source :
- Vaccine [ 0264-410X ] ; 1998.
English descriptors
- Teeft :
- Adult bone marrow transplant recipients, Antibody, Antibody response, Antibody responses, Antigenic, Antigenic variation, Attenuated, Attenuated influenza, Attenuated vaccines, Belshe, Bronchiolitis, Chanock, Chiba, Cotton rats, Crowe, Cytotoxic, Epidemiol, Experimental infection, Experimental studies, Glezen, Glycoprotein, Heterosubtypic immunity, High levels, Hlnl, Immun, Immune, Immune response, Immune responses, Immunity, Immunization, Immunogenicity, Immunoglobulin, Immunol, Infant, Infection, Influenza, Influenza virus, Influenza viruses, Karron, Maternal antibodies, Maternal antibody, Microbial, Monoclonal antibodies, Nasal wash, Nasopharyngeal secretion, Natural infection, Neutralizing, Neutralizing antibodies, Nonhuman primates, Ogra, Parainfluenza, Parainfluenza type, Parainfluenza virus type, Passive transfer, Pediatr, Peripheral blood, Previous infection, Primary infection, Primary role, Protective efficacy, Recombinant, Reinfection, Respiratory, Respiratory syncytial, Respiratory syncytial virus, Respiratory syncytial virus infection, Respiratory syncytial virus infections, Respiratory syncytial virus vaccine, Respiratory tract, Respiratory virus infection, Respiratory viruses, Routine immunizations, Seronegative, Seronegative chimpanzees, Seronegative infants, Seronegative subjects, Serum antibodies, Severe disease, Subclass, Subgroup, Syncytial, Syncytial virus, Syncytial virus infection, Taber, Third infections, Titre, Vaccine, Vaccine candidates, Vaccinee, Viral, Virus, Virus infection, Virus infections, Virus replication, Virus vaccines, Welliver, Young children, Young infants.
Abstract
Abstract: Respiratory viruses such as respiratory syncytial virus (RSV), the parainfluenza viruses (PIV), and the influenza viruses cause severe lower respiratory tract diseases in infants and children throughout the world. Experimental live attenuated vaccines for each of these viruses are being developed for intranasal administration in the first weeks or months of life. A variety of promising RSV, PIV-3, and influenza virus vaccine strains have been developed by classical biological methods, evaluated extensively in preclinical and clinical studies, and shown to be attenuated and genetically stable. The ongoing clinical evaluation of these vaccine candidates, coupled with recent major advances in the ability to develop genetically engineered viruses with specified mutations, may allow the rapid development of respiratory virus strains that possess ideal levels of replicative capacity and genetic stability in vivo. A major remaining obstacle to successful immunization of infants against respiratory virus associated disease may be the relatively poor immune response of very young infants to primary virus infection. This paper reviews the immune correlates of protection against disease caused by these viruses, immune responses of infants to naturally-acquired infection, and immune responses of infants to experimental infection with candidate vaccine viruses.
Url:
DOI: 10.1016/S0264-410X(98)00103-0
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001769
Links to Exploration step
ISTEX:1455B9E8FAFEC189D10361F23B31E5DD0C21B2A4Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Immune responses of infants to infection with respiratory viruses and live attenuated respiratory virus candidate vaccines</title><author><name sortKey="Crowe Jr, James E" sort="Crowe Jr, James E" uniqKey="Crowe Jr J" first="James E." last="Crowe Jr.">James E. Crowe Jr.</name><affiliation wicri:level="1"><mods:affiliation>Division of Pediatric Infectious Diseases, Vanderbilt University Medical School, D-7235 Medical Center North, 1161 21st Avenue South, Nashville, TN 37232-2581, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Pediatric Infectious Diseases, Vanderbilt University Medical School, D-7235 Medical Center North, 1161 21st Avenue South, Nashville, TN 37232-2581</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>E-mail: james.e.crowe@vanderbilt.edu</mods:affiliation><country wicri:rule="url">États-Unis</country></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1455B9E8FAFEC189D10361F23B31E5DD0C21B2A4</idno><date when="1998" year="1998">1998</date><idno type="doi">10.1016/S0264-410X(98)00103-0</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-7S3PBJ9D-B/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001769</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001769</idno><idno type="wicri:Area/Istex/Curation">001769</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Immune responses of infants to infection with respiratory viruses and live attenuated respiratory virus candidate vaccines</title><author><name sortKey="Crowe Jr, James E" sort="Crowe Jr, James E" uniqKey="Crowe Jr J" first="James E." last="Crowe Jr.">James E. Crowe Jr.</name><affiliation wicri:level="1"><mods:affiliation>Division of Pediatric Infectious Diseases, Vanderbilt University Medical School, D-7235 Medical Center North, 1161 21st Avenue South, Nashville, TN 37232-2581, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Pediatric Infectious Diseases, Vanderbilt University Medical School, D-7235 Medical Center North, 1161 21st Avenue South, Nashville, TN 37232-2581</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>E-mail: james.e.crowe@vanderbilt.edu</mods:affiliation><country wicri:rule="url">États-Unis</country></affiliation></author></analytic><monogr></monogr><series><title level="j">Vaccine</title><title level="j" type="abbrev">JVAC</title><idno type="ISSN">0264-410X</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1998">1998</date><biblScope unit="volume">16</biblScope><biblScope unit="issue">14–15</biblScope><biblScope unit="page" from="1423">1423</biblScope><biblScope unit="page" to="1432">1432</biblScope></imprint><idno type="ISSN">0264-410X</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0264-410X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Adult bone marrow transplant recipients</term><term>Antibody</term><term>Antibody response</term><term>Antibody responses</term><term>Antigenic</term><term>Antigenic variation</term><term>Attenuated</term><term>Attenuated influenza</term><term>Attenuated vaccines</term><term>Belshe</term><term>Bronchiolitis</term><term>Chanock</term><term>Chiba</term><term>Cotton rats</term><term>Crowe</term><term>Cytotoxic</term><term>Epidemiol</term><term>Experimental infection</term><term>Experimental studies</term><term>Glezen</term><term>Glycoprotein</term><term>Heterosubtypic immunity</term><term>High levels</term><term>Hlnl</term><term>Immun</term><term>Immune</term><term>Immune response</term><term>Immune responses</term><term>Immunity</term><term>Immunization</term><term>Immunogenicity</term><term>Immunoglobulin</term><term>Immunol</term><term>Infant</term><term>Infection</term><term>Influenza</term><term>Influenza virus</term><term>Influenza viruses</term><term>Karron</term><term>Maternal antibodies</term><term>Maternal antibody</term><term>Microbial</term><term>Monoclonal antibodies</term><term>Nasal wash</term><term>Nasopharyngeal secretion</term><term>Natural infection</term><term>Neutralizing</term><term>Neutralizing antibodies</term><term>Nonhuman primates</term><term>Ogra</term><term>Parainfluenza</term><term>Parainfluenza type</term><term>Parainfluenza virus type</term><term>Passive transfer</term><term>Pediatr</term><term>Peripheral blood</term><term>Previous infection</term><term>Primary infection</term><term>Primary role</term><term>Protective efficacy</term><term>Recombinant</term><term>Reinfection</term><term>Respiratory</term><term>Respiratory syncytial</term><term>Respiratory syncytial virus</term><term>Respiratory syncytial virus infection</term><term>Respiratory syncytial virus infections</term><term>Respiratory syncytial virus vaccine</term><term>Respiratory tract</term><term>Respiratory virus infection</term><term>Respiratory viruses</term><term>Routine immunizations</term><term>Seronegative</term><term>Seronegative chimpanzees</term><term>Seronegative infants</term><term>Seronegative subjects</term><term>Serum antibodies</term><term>Severe disease</term><term>Subclass</term><term>Subgroup</term><term>Syncytial</term><term>Syncytial virus</term><term>Syncytial virus infection</term><term>Taber</term><term>Third infections</term><term>Titre</term><term>Vaccine</term><term>Vaccine candidates</term><term>Vaccinee</term><term>Viral</term><term>Virus</term><term>Virus infection</term><term>Virus infections</term><term>Virus replication</term><term>Virus vaccines</term><term>Welliver</term><term>Young children</term><term>Young infants</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Respiratory viruses such as respiratory syncytial virus (RSV), the parainfluenza viruses (PIV), and the influenza viruses cause severe lower respiratory tract diseases in infants and children throughout the world. Experimental live attenuated vaccines for each of these viruses are being developed for intranasal administration in the first weeks or months of life. A variety of promising RSV, PIV-3, and influenza virus vaccine strains have been developed by classical biological methods, evaluated extensively in preclinical and clinical studies, and shown to be attenuated and genetically stable. The ongoing clinical evaluation of these vaccine candidates, coupled with recent major advances in the ability to develop genetically engineered viruses with specified mutations, may allow the rapid development of respiratory virus strains that possess ideal levels of replicative capacity and genetic stability in vivo. A major remaining obstacle to successful immunization of infants against respiratory virus associated disease may be the relatively poor immune response of very young infants to primary virus infection. This paper reviews the immune correlates of protection against disease caused by these viruses, immune responses of infants to naturally-acquired infection, and immune responses of infants to experimental infection with candidate vaccine viruses.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001769 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 001769 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:1455B9E8FAFEC189D10361F23B31E5DD0C21B2A4
|texte= Immune responses of infants to infection with respiratory viruses and live attenuated respiratory virus candidate vaccines
}}
| This area was generated with Dilib version V0.6.33. |  |